Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

5.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 682
Open 5.500
Bid (Size) 5.110 (100)
Ask (Size) 5.470 (100)
Prev. Close 5.500
Today's Range 5.500 - 5.500
52wk Range 4.800 - 13.69
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
-39.8%
-39.8%
1 Month
-4.2%
-4.2%
3 Month
-21.9%
-21.9%
6 Month
-45.6%
-45.6%
1 Year
-27.9%
-27.9%

More News

Read More
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ↗
Via Chartmill
News headline image
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Upcoming Investor Conferences
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aligos Therapeutics, Inc. - Common stock publicly traded?
Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
What is the current price of Aligos Therapeutics, Inc. - Common stock?
The current price of Aligos Therapeutics, Inc. - Common stock is 5.500
When was Aligos Therapeutics, Inc. - Common stock last traded?
The last trade of Aligos Therapeutics, Inc. - Common stock was at 06/25/26 04:00 PM ET
What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
The market capitalization of Aligos Therapeutics, Inc. - Common stock is 236.17M
How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
Aligos Therapeutics, Inc. - Common stock has 236M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.